Study identifier:D5881C00005
ClinicalTrials.gov identifier:NCT02209766
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics in Healthy Male Japanese (Single-blind, Randomized, Placebo-controlled) and Caucasian (Open-label) Subjects After Single and Once Daily Multiple Oral Doses of D5884
Healthy
Phase 1
Yes
D5884, Placebo
Male
86
Interventional
20 Years - 45 Years
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verified 01 Apr 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: D5884 D5884 capsule, Per oral(po) | Drug: D5884 1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian |
Placebo Comparator: Placebo Placebo capsule, po | Drug: Placebo 1st cohort: Dose 1(2g) D5884(n=3) in Japanese 2nd cohort: Dose 2(4g) D5884(n=3) in Japanese |